Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Extracellular vesicle-encapsulated miR-22-3p from bone marrow mesenchymal stem cell promotes osteogenic differentiation via FTO inhibition

Fig. 2

Optimization for BMSC treatment with EVs at 50 μg/mL concentration. BMSC were divided into BMSC-EV/miR-22-3p inhibitor, BMSC-EV/inhibitor-NC group, or BMSC-EV groups. a TEM analysis of EVs shows spherical morphology (scale bar = 200 nm). b NTA analysis shows the size of EVs. c Immunoblotting was adopted to confirm the expression of EV marker protein CD9, CD63, β-tubulin (cytoplasmic marker), or histone 1 (nuclear marker). d RT-qPCR was adopted to determined miR-22-3p content in isolated EVs. e The content of miR-22-3p in BMSCs was analyzed by RT-qPCR after isolated EVs were incubated with BMSCs for 4 h. f The contents of miR-22-3p in BMSCs of 50 μg/mL group and 100 μg/mL group were analyzed by RT-qPCR. g Fluorescence microscopy showed that PKH26-labeled EVs (red) were gradually internalized by BMSCs (× 400). *p < 0.05 vs. the BMSC-EV/inhibitor-NC group, #p < 0.05 vs. the PBS group, and p < 0.05 vs. EVs at the concentration of 100 μg/mL. Comparison between two groups was performed by unpaired t test. Comparison of data between multiple groups was performed by one-way ANOVA. Tukey’s was used for post hoc tests

Back to article page